Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02184533 · ClinicalTrials.gov registry record · Phase 1
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
A Phase 1 study of Multiple Myeloma and Recurrent Prostate Cancer, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02184533 is a Phase 1 study of Multiple Myeloma and Recurrent Prostate Cancer that has completed, run by Stanford University. The registered enrollment target is 15 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02184533, a Phase 1 study of Multiple Myeloma and Recurrent Prostate Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite when administered in combination with radiation therapy to subjects with metastatic cancer based on safety and tolerability.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- OTHER pharmacological study
- RADIATION radiation therapy
- DRUG sodium selenite
Study Locations (1)
California
- Stanford University, School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02184533
The ClinicalTrials.gov registry entry for NCT02184533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02184533 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02184533 about?
NCT02184533 is a clinical study titled "Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer". The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite when administered in combination with radiation therapy to subjects with metastatic cancer based on safety and tolerability.
What is the current status of trial NCT02184533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-07. Estimated completion is 2018-05.
What conditions does trial NCT02184533 study?
This clinical trial studies the following conditions: Multiple Myeloma, Recurrent Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-Resistant Prostate Cancer.
What interventions are being tested in trial NCT02184533?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), pharmacological study (OTHER), radiation therapy (RADIATION), sodium selenite (DRUG).
Who is sponsoring clinical trial NCT02184533?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02184533 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.